Design and characterization of non-Phosphopeptide inhibitors for Src family SH2 domains
- 7 September 2002
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (19) , 2711-2714
- https://doi.org/10.1016/s0960-894x(02)00523-1
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Antagonists of the Src Homology 2 (SH2) Domains of Grb2, Src, Lck and ZAP-70Current Medicinal Chemistry, 2001
- The Src Homology-2 Domains (SH2 Domains) of the Protein Tyrosine Kinase p56 lck Structure, Mechanism and Drug DesignCurrent Drug Targets, 2000
- Recent Advances in the Design and Synthesis of SH2 Inhibitorsof Src, Grb2 and ZAP-70.Current Medicinal Chemistry, 2000
- SH2-Directed Ligands of the Lck Tyrosine KinaseJournal of Medicinal Chemistry, 2000
- Ligands for the Tyrosine Kinase p56lck SH2 Domain: Discovery of Potent Dipeptide Derivatives with Monocharged, Nonhydrolyzable Phosphate ReplacementsJournal of Medicinal Chemistry, 1999
- Acquisition of High-Affinity, SH2-Targeted Ligands via a Spatially Focused LibraryJournal of Medicinal Chemistry, 1999
- l-Dopa: A Powerful Nonphosphorylatable Tyrosine Mimetic for pp60c-srcJournal of the American Chemical Society, 1997
- Chapter 24. SH2 and SH3 Domains: Choreographers of Multiple Signaling PathwaysPublished by Elsevier ,1995
- SH2 domains recognize specific phosphopeptide sequencesPublished by Elsevier ,1993
- Oncogenes and signal transductionCell, 1991